# Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

> **NCT00511576** · PHASE1 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Pulmonary Cancer
- Non-Small-Cell Lung Carcinoma
- Prostate Cancer
- Prostatic Cancer
- Gastric Cancer
- Stomach Cancer

## Interventions

- **DRUG:** MGCD0103 & Docetaxel

## Key facts

- **NCT ID:** NCT00511576
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 54 (ESTIMATED)
- **Why stopped:** Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511576, "Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00511576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*